Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Exact Sciences Corporation lost $1.13 a share on $2.5 billion in sales in FY2023. The current analyst firm consensus sees similar per share losses in FY2024, even as sales rise to $2.83 billion.

WEDC will increase Exact Sciences’ enterprise tax credits from $9 million to $27.5 million according to the press release. Enterprise tax credits serve as a sum of dollar credits companies can use to ...

Exact Sciences’ proprietary technology platform, Exact Nexus, enabled electronic connections with nearly 0.25 million providers who ordered Cologuard this year, along with 24 million patients ...

Summary According to ARK’s research, Exact Sciences has been a pioneering force in the growing field of oncology testing and will likely remain so during the next five years. Exact’s ...

A n updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.